1-anilino-8-naphthalenesulfonate has been researched along with Metabolic Syndrome in 80 studies
1-anilino-8-naphthalenesulfonate: RN given refers to parent cpd
8-anilinonaphthalene-1-sulfonic acid : A naphthalenesulfonic acid that is naphthalene-1-sulfonic acid substituted by a phenylamino group at position 8.
Metabolic Syndrome: A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic syndrome include ABDOMINAL OBESITY; atherogenic DYSLIPIDEMIA; HYPERTENSION; HYPERGLYCEMIA; INSULIN RESISTANCE; a proinflammatory state; and a prothrombotic (THROMBOSIS) state.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We previously demonstrated that children with Down syndrome (DS) exhibited a greater risk of steatosis than the general pediatric population." | 7.96 | PNPLA3 gene polymorphism is associated with liver steatosis in children with Down syndrome. ( Alisi, A; Crudele, A; Di Camillo, C; Mosca, A; Novelli, A; Raponi, M; Sartorelli, MR; Scoppola, V; Tarani, L; Valentini, D; Villani, A, 2020) |
| "Corchorus olitorius is effective as orlistat in preventing obesity, hyperlipidaemia, steatosis and insulin resistance." | 7.91 | Amelioration of experimental metabolic syndrome induced in rats by orlistat and Corchorus olitorius leaf extract; role of adipo/cytokines. ( Al-Zokeim, NI; El-Sers, DA; Gomaa, AA; Gomaa, MA, 2019) |
| " We hypothesized that dietary epigallocatechin-3-gallate (EGCG) could reverse metabolic syndrome in high fat-fed obese C57bl/6J mice, and that these effects were related to inhibition of pancreatic lipase (PL)." | 7.78 | (-)-Epigallocatechin-3-gallate inhibits pancreatic lipase and reduces body weight gain in high fat-fed obese mice. ( Grove, KA; Kennett, MJ; Lambert, JD; Sae-tan, S, 2012) |
| "Orlistat was well tolerated." | 6.71 | The ORLIstat and CArdiovascular risk profile in patients with metabolic syndrome and type 2 DIAbetes (ORLICARDIA) Study. ( Athyros, VG; Bousboulas, SH; Didangelos, TP; Dimitriou, KC; Karamanos, BG; Karamitsos, DT; Pappas, SI; Sambanis, CL; Spanou, EA; Thanopoulou, AK, 2004) |
| "Recently we have demonstrated that treatment with niacin raises adiponectin between 52% and 95% in patients with the metabolic syndrome." | 5.13 | Preferential increase in high-molecular weight adiponectin after niacin. ( Luley, C; Westphal, S, 2008) |
| "We previously demonstrated that children with Down syndrome (DS) exhibited a greater risk of steatosis than the general pediatric population." | 3.96 | PNPLA3 gene polymorphism is associated with liver steatosis in children with Down syndrome. ( Alisi, A; Crudele, A; Di Camillo, C; Mosca, A; Novelli, A; Raponi, M; Sartorelli, MR; Scoppola, V; Tarani, L; Valentini, D; Villani, A, 2020) |
| "Corchorus olitorius is effective as orlistat in preventing obesity, hyperlipidaemia, steatosis and insulin resistance." | 3.91 | Amelioration of experimental metabolic syndrome induced in rats by orlistat and Corchorus olitorius leaf extract; role of adipo/cytokines. ( Al-Zokeim, NI; El-Sers, DA; Gomaa, AA; Gomaa, MA, 2019) |
| " We hypothesized that dietary epigallocatechin-3-gallate (EGCG) could reverse metabolic syndrome in high fat-fed obese C57bl/6J mice, and that these effects were related to inhibition of pancreatic lipase (PL)." | 3.78 | (-)-Epigallocatechin-3-gallate inhibits pancreatic lipase and reduces body weight gain in high fat-fed obese mice. ( Grove, KA; Kennett, MJ; Lambert, JD; Sae-tan, S, 2012) |
| "MAFLD is closely intertwined with type 2 diabetes, obesity, dyslipidaemia, all linked to a rise in the risk of cardiovascular disease (CVDs)." | 2.72 | Nonalcoholic fatty liver disease or metabolic dysfunction-associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches. ( Corsini, A; Dongiovanni, P; Paolini, E; Ruscica, M; Sirtori, CR, 2021) |
| "Orlistat was well tolerated." | 2.71 | The ORLIstat and CArdiovascular risk profile in patients with metabolic syndrome and type 2 DIAbetes (ORLICARDIA) Study. ( Athyros, VG; Bousboulas, SH; Didangelos, TP; Dimitriou, KC; Karamanos, BG; Karamitsos, DT; Pappas, SI; Sambanis, CL; Spanou, EA; Thanopoulou, AK, 2004) |
| "Nonalcoholic fatty liver disease (NAFLD) affects around a quarter of the global population, paralleling worldwide increases in obesity and metabolic syndrome." | 2.66 | Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology. ( Eslam, M; George, J, 2020) |
| "Both individuals with type 1 diabetes mellitus (mean difference = -1." | 2.66 | Low serum amylase, lipase, and trypsin as biomarkers of metabolic disorders: A systematic review and meta-analysis. ( Cho, J; Ko, J; Petrov, MS, 2020) |
| "Furthermore, it also indicated that nonalcoholic steatohepatitis (NASH) was more frequently observed in G allele carriers among paediatric and adolescent NAFLD patients." | 2.66 | Effect of the patatin-like phospholipase domain containing 3 gene (PNPLA3) I148M polymorphism on the risk and severity of nonalcoholic fatty liver disease and metabolic syndromes: A meta-analysis of paediatric and adolescent individuals. ( Hua, W; Ji, C; Li, J; Rui, J; Shi, B; Xie, C; Yang, X; Zhao, Y, 2020) |
| "Nonalcoholic fatty liver disease (NAFLD), including nonalcoholic steatohepatitis (NASH), causes hepatic fibrosis, cirrhosis and hepatocellular carcinoma (HCC)." | 2.66 | Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma. ( Goto, T; Hirotsu, Y; Kanda, T; Masuzaki, R; Moriyama, M; Omata, M, 2020) |
| "Non-obese NAFLD is common, particularly in South America and among people aged ≥45 years." | 2.66 | Epidemiology of nonalcoholic fatty liver disease in non-obese populations: Meta-analytic assessment of its prevalence, genetic, metabolic, and histological profiles. ( Fan, JG; Wong, VW; Zou, ZY, 2020) |
| "First described in 1980, nonalcoholic fatty liver disease (NAFLD) has become more common although the exact incidence and prevalence is unknown." | 2.58 | NAFLD-NASH: An Under-Recognized Epidemic. ( Faselis, C; Jennings, J; Yao, MD, 2018) |
| "Nonalcoholic fatty liver disease (NAFLD) and metabolic syndrome (MS) are highly prevalent, affecting approximately one-third of the US population." | 2.58 | Nonalcoholic Fatty Liver Disease and Metabolic Syndrome. ( Kim, D; Kim, WR; Touros, A, 2018) |
| "Posttransplant metabolic syndrome is a common occurrence that increases the risk of steatosis in the graft liver." | 2.58 | Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis in Liver Transplantation. ( Carter, D; Chang, C; Dieterich, DT, 2018) |
| "Nonalcoholic fatty liver disease is emerging as the most common cause of chronic liver disease worldwide." | 2.58 | Risk Factors for the Development of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Genetics. ( Bernstein, DE; Lim, HW, 2018) |
| "Currently, the population prevalence of NAFLD in Asia is around 25%, like many Western countries." | 2.55 | New trends on obesity and NAFLD in Asia. ( Fan, JG; Kim, SU; Wong, VW, 2017) |
| "NAFLD is increasing in prevalence and is presently the second most frequent indication for liver transplantation." | 2.53 | Bidirectional Relationships and Disconnects between NAFLD and Features of the Metabolic Syndrome. ( Byrne, CD; Wainwright, P, 2016) |
| "Nonalcoholic fatty liver disease (NAFLD) is emerging as the most common cause of liver disease in the United States." | 2.53 | The Prevalence and Pathobiology of Nonalcoholic Fatty Liver Disease in Patients of Different Races or Ethnicities. ( Gaglio, PJ; Kalia, HS, 2016) |
| "Non-alcoholic fatty liver disease (NAFLD) increases risk of mortality from liver and cardiovascular disease (CVD) and is the major cause of hepatocellular carcinoma (HCC), which may develop without cirrhosis." | 2.53 | Diagnosis of non-alcoholic fatty liver disease (NAFLD). ( Yki-Järvinen, H, 2016) |
| "Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome and comprises a liver disease spectrum ranging from steatosis to nonalcoholic steatohepatitis (NASH) with risk of progression to liver cirrhosis and hepatocellular carcinoma (HCC)." | 2.52 | Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH. ( Halilbasic, E; Hofer, H; Kazemi-Shirazi, L; Kienbacher, C; Munda, P; Rechling, C; Trauner, M; Traussnigg, S, 2015) |
| "Nonalcoholic fatty liver disease (NAFLD) is increasingly being diagnosed worldwide and is strongly associated with the features of metabolic syndrome." | 2.52 | A Perspective on Metabolic Syndrome and Nonalcoholic Fatty Liver Disease. ( Byrne, CD; Targher, G, 2015) |
| "Half of people with NAFLD carry at least one variant (G) allele at rs738409 in the PNPLA3 gene, which is associated with high liver fat content." | 2.50 | Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. ( Yki-Järvinen, H, 2014) |
| "The pathogenesis of type 2 diabetes involves both insulin resistance and defects in insulin secretion." | 2.46 | Liver fat in the pathogenesis of insulin resistance and type 2 diabetes. ( Yki-Järvinen, H, 2010) |
| "Patients with type 2 diabetes mellitus or the metabolic syndrome have a unique dyslipidemia characterized by hypertriglyceridemia; elevated blood levels of apolipoprotein B; small, dense low-density lipoprotein (LDL) cholesterol; and low levels of high-density lipoprotein (HDL) cholesterol, in particular HDL(2)-C." | 2.42 | Dyslipidemia in the metabolic syndrome and type 2 diabetes mellitus. ( Ayyobi, AF; Brunzell, JD, 2003) |
| "Non-alcoholic fatty liver disease (NAFLD) shares several risk factors with atherosclerosis, as it is associated with components of the metabolic syndrome." | 1.72 | Association of rs738409 Polymorphism in Adiponutrin Gene with Liver Steatosis and Atherosclerosis Risk Factors in Greek Children and Adolescents. ( Emmanouilidou-Fotoulaki, E; Fotoulaki, M; Kavga, M; Lambropoulos, AF; Papadopoulou-Legbelou, K; Sotiriadou, F; Stasinou, E, 2022) |
| "The histological spectrum of NAFLD was classified according to the NASH clinical research network scoring system." | 1.62 | Individualized Polygenic Risk Score Identifies NASH in the Eastern Asia Region: A Derivation and Validation Study. ( Byrne, CD; Chen, SD; Chen, YP; Gao, F; Kim, W; Lee, DH; Targher, G; Wang, XD; Wu, XX; Zheng, KI; Zheng, MH, 2021) |
| "NAFLD is multi-factorial in pathogenesis with some genetic predisposition." | 1.56 | The effect of PNPLA3 polymorphism as gain in function mutation in the pathogenesis of non-alcoholic fatty liver disease. ( Akkız, H; Delik, A; Dinçer, S, 2020) |
| "Non-alcoholic fatty liver disease (NAFLD) is commonly diagnosed in patients presenting with metabolic syndrome (MetS) and has been associated with single nucleotide polymorphisms of rs738409 in the patatin-like phospholipase domain containing 3 (PNPLA3) gene." | 1.56 | Association of metabolic syndrome and patatin-like phospholipase 3 - rs738409 gene variant in non-alcoholic fatty liver disease among a Chennai-based south Indian population. ( Karthick, R; Mohan, N; Narayanasamy, K; Panneerselvam, P; Prakash, R; Rajaram, M; Ramachandran, A, 2020) |
| "A total of 208 obese NAFLD patients without (n=125) and with prediabetes (n=83) were included." | 1.51 | PNPLA3 I148M Polymorphism in Patients with Nonalcoholic Fatty Liver Disease, Obesity and Prediabetes. ( Alexiev, A; Assyov, Y; Gateva, A; Ivanova, I; Ivanova, R; Ivanova-Boyanova, R; Kamenov, Z; Karamfilova, V; Mateva, L; Savov, A; Vlahova, Z; Yaneva, N, 2019) |
| "non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disorder in the western world." | 1.51 | Comparative study of overweight and obese patients with nonalcoholic fatty liver disease. ( Aller, R; Antolín, B; Burgueño Gomez, B; de Luis Román, D; Durà, M; Fernández, N; Fernández-Rodríguez, C; García, C; Lorenzo, S; Pina, M; Sigüenza, R, 2019) |
| "One-hundred seventy-four NAFLD patients, who underwent liver biopsy for diagnostic work-up, were studied." | 1.46 | Low hepatic copper content and PNPLA3 polymorphism in non-alcoholic fatty liver disease in patients without metabolic syndrome. ( Aigner, E; Datz, C; Ferenci, P; Huber-Schönauer, U; Kienbacher, C; Stadlmayr, A; Stättermayer, AF; Steindl-Munda, P; Trauner, M; Traussnigg, S; Wrba, F, 2017) |
| "Obesity is associated with non-alcoholic fatty liver disease (NAFLD), and the patatin-like phospholipase 3 (PNPLA3) rs738409 (Ile148Met, C>G) gene polymorphism is one of the most important genetic determinants of NAFLD." | 1.42 | Patatin-like phospholipase 3 (rs738409) gene polymorphism is associated with increased liver enzymes in obese adolescents and metabolic syndrome in all ages. ( Aigner, E; Baumgartner, BG; Haybaeck, J; Lackner, C; Mangge, H; Prüller, F; Reininghaus, EZ; Schnedl, WJ; Stauber, R; Weghuber, D; Zelzer, S, 2015) |
| "The prevalence of GG genotype in NAFLD subjects was 20." | 1.40 | PNPLA3 gene polymorphism accounts for fatty liver in community subjects without metabolic syndrome. ( Chan, AW; Chan, HL; Chan, HY; Chan, RS; Chim, AM; Choi, PC; Chu, WC; Shen, J; Wong, GL; Wong, VW; Woo, J; Yeung, DK, 2014) |
| "Metabolic syndrome was defined according to ATPIII modified criteria." | 1.40 | Non-alcoholic fatty liver disease, metabolic syndrome and patatin-like phospholipase domain-containing protein3 gene variants. ( Angelico, F; Arca, M; Baratta, F; Brancorsini, M; D'Erasmo, L; Del Ben, M; Di Costanzo, A; Loffredo, L; Pastori, D; Pignatelli, P; Polimeni, L; Violi, F, 2014) |
| "Obesity is a complex metabolic disorder that often manifests with a strong genetic component in humans." | 1.39 | Altered lipid homeostasis in Drosophila InsP3 receptor mutants leads to obesity and hyperphagia. ( Hasan, G; Kumar, S; Metya, SK; Sadaf, S; Schwudke, D; Subramanian, M, 2013) |
| "The ECOPD was defined as worsening of symptoms requiring increased use of rescue medications and/or need for either systemic steroids or antibiotics or that led to emergency room visit or hospitalizations during 12 months follow-up." | 1.36 | Metabolic syndrome is associated with increased risk of acute exacerbation of COPD: a preliminary study. ( Erayman, Z; Gürsoy, A; Küpeli, E; Sahin, T; Ulasli, SS; Ulubay, G, 2010) |
| "(1) The treatment of obesity is based on calorie reduction and moderate physical activity." | 1.33 | Rimonabant: new drug. Obesity: loss of a few kilos, many questions. ( , 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (15.00) | 29.6817 |
| 2010's | 51 (63.75) | 24.3611 |
| 2020's | 17 (21.25) | 2.80 |
| Authors | Studies |
|---|---|
| Stasinou, E | 1 |
| Emmanouilidou-Fotoulaki, E | 1 |
| Kavga, M | 1 |
| Sotiriadou, F | 1 |
| Lambropoulos, AF | 1 |
| Fotoulaki, M | 1 |
| Papadopoulou-Legbelou, K | 1 |
| Lai, HH | 1 |
| Yeh, KY | 1 |
| Hsu, HM | 1 |
| Her, GM | 1 |
| Klobučar, I | 2 |
| Stadler, JT | 1 |
| Klobučar, L | 2 |
| Lechleitner, M | 2 |
| Trbušić, M | 3 |
| Pregartner, G | 3 |
| Berghold, A | 3 |
| Habisch, H | 2 |
| Madl, T | 2 |
| Marsche, G | 2 |
| Frank, S | 3 |
| Degoricija, V | 3 |
| Mahdy, NE | 1 |
| Abdel-Baki, PM | 1 |
| El-Rashedy, AA | 1 |
| Ibrahim, RM | 1 |
| Antileo-Laurie, J | 1 |
| Theoduloz, C | 1 |
| Burgos-Edwards, A | 1 |
| Jiménez-Aspee, F | 2 |
| Márquez, K | 1 |
| Fischer, M | 1 |
| Schmeda-Hirschmann, G | 2 |
| Eslam, M | 1 |
| George, J | 1 |
| Ko, J | 1 |
| Cho, J | 1 |
| Petrov, MS | 1 |
| Karamfilova, V | 1 |
| Gateva, A | 1 |
| Assyov, Y | 1 |
| Alexiev, A | 1 |
| Savov, A | 1 |
| Yaneva, N | 1 |
| Ivanova, I | 1 |
| Ivanova-Boyanova, R | 1 |
| Ivanova, R | 1 |
| Vlahova, Z | 1 |
| Mateva, L | 1 |
| Kamenov, Z | 1 |
| Narayanasamy, K | 1 |
| Karthick, R | 1 |
| Panneerselvam, P | 1 |
| Mohan, N | 1 |
| Ramachandran, A | 1 |
| Prakash, R | 1 |
| Rajaram, M | 1 |
| Li, J | 2 |
| Hua, W | 1 |
| Ji, C | 1 |
| Rui, J | 1 |
| Zhao, Y | 1 |
| Xie, C | 1 |
| Shi, B | 1 |
| Yang, X | 1 |
| Kanda, T | 1 |
| Goto, T | 1 |
| Hirotsu, Y | 1 |
| Masuzaki, R | 1 |
| Moriyama, M | 1 |
| Omata, M | 1 |
| Delik, A | 1 |
| Akkız, H | 1 |
| Dinçer, S | 1 |
| Zou, ZY | 1 |
| Wong, VW | 3 |
| Fan, JG | 2 |
| Cicolari, S | 1 |
| Dacrema, M | 1 |
| Tsetegho Sokeng, AJ | 1 |
| Xiao, J | 1 |
| Atchan Nwakiban, AP | 1 |
| Di Giovanni, C | 1 |
| Santarcangelo, C | 1 |
| Magni, P | 2 |
| Daglia, M | 1 |
| Valentini, D | 1 |
| Mosca, A | 1 |
| Di Camillo, C | 1 |
| Crudele, A | 2 |
| Sartorelli, MR | 1 |
| Scoppola, V | 1 |
| Tarani, L | 1 |
| Villani, A | 1 |
| Raponi, M | 1 |
| Novelli, A | 1 |
| Alisi, A | 2 |
| Dongiovanni, P | 2 |
| Paolini, E | 1 |
| Corsini, A | 1 |
| Sirtori, CR | 1 |
| Ruscica, M | 2 |
| Gao, F | 1 |
| Zheng, KI | 1 |
| Chen, SD | 1 |
| Lee, DH | 1 |
| Wu, XX | 1 |
| Wang, XD | 1 |
| Targher, G | 2 |
| Byrne, CD | 3 |
| Chen, YP | 1 |
| Kim, W | 1 |
| Zheng, MH | 1 |
| Potočnjak, I | 1 |
| Terešak, SD | 1 |
| Radulović, B | 1 |
| Tiran, B | 1 |
| Kim, SU | 1 |
| Jennings, J | 1 |
| Faselis, C | 1 |
| Yao, MD | 1 |
| Jakubczyk, A | 1 |
| Karaś, M | 1 |
| Złotek, U | 1 |
| Szymanowska, U | 1 |
| Kim, D | 1 |
| Touros, A | 1 |
| Kim, WR | 1 |
| Carter, D | 1 |
| Dieterich, DT | 1 |
| Chang, C | 1 |
| Lim, HW | 1 |
| Bernstein, DE | 1 |
| Tortora, R | 1 |
| Rispo, A | 1 |
| Imperatore, N | 1 |
| Ferretti, F | 1 |
| Nobili, V | 1 |
| Miele, L | 1 |
| Gerbino, N | 1 |
| Caporaso, N | 1 |
| Morisco, F | 1 |
| Gomaa, AA | 1 |
| El-Sers, DA | 1 |
| Al-Zokeim, NI | 1 |
| Gomaa, MA | 1 |
| Aller, R | 1 |
| Burgueño Gomez, B | 1 |
| Sigüenza, R | 1 |
| Fernández-Rodríguez, C | 1 |
| Fernández, N | 1 |
| Antolín, B | 1 |
| Durà, M | 1 |
| Pina, M | 1 |
| Lorenzo, S | 1 |
| García, C | 1 |
| de Luis Román, D | 1 |
| Chen, Z | 1 |
| Zhang, D | 1 |
| Guo, JJ | 1 |
| Tao, W | 1 |
| Gong, RX | 1 |
| Yao, L | 1 |
| Zhang, XL | 1 |
| Cao, WG | 1 |
| Gong, L | 1 |
| Liu, S | 1 |
| Zhang, Y | 2 |
| Zhang, C | 2 |
| Tian, M | 1 |
| Lu, H | 1 |
| Bu, P | 1 |
| Yang, J | 1 |
| Ouyang, C | 1 |
| Jiang, X | 1 |
| Wu, J | 1 |
| Min, Q | 1 |
| Zhang, W | 1 |
| Subramanian, M | 1 |
| Metya, SK | 1 |
| Sadaf, S | 1 |
| Kumar, S | 1 |
| Schwudke, D | 1 |
| Hasan, G | 1 |
| Dalar, A | 1 |
| Türker, M | 1 |
| Zabaras, D | 1 |
| Konczak, I | 2 |
| Hyysalo, J | 1 |
| Männistö, VT | 1 |
| Zhou, Y | 1 |
| Arola, J | 1 |
| Kärjä, V | 1 |
| Leivonen, M | 1 |
| Juuti, A | 1 |
| Jaser, N | 1 |
| Lallukka, S | 1 |
| Käkelä, P | 1 |
| Venesmaa, S | 1 |
| Simonen, M | 1 |
| Saltevo, J | 1 |
| Moilanen, L | 1 |
| Korpi-Hyövalti, E | 1 |
| Keinänen-Kiukaanniemi, S | 1 |
| Oksa, H | 1 |
| Orho-Melander, M | 2 |
| Valenti, L | 2 |
| Fargion, S | 2 |
| Pihlajamäki, J | 1 |
| Peltonen, M | 2 |
| Yki-Järvinen, H | 5 |
| Shen, J | 1 |
| Wong, GL | 1 |
| Chan, HL | 1 |
| Chan, HY | 1 |
| Yeung, DK | 1 |
| Chan, RS | 1 |
| Chim, AM | 1 |
| Chan, AW | 1 |
| Choi, PC | 1 |
| Woo, J | 1 |
| Chu, WC | 1 |
| Miksztowicz, V | 1 |
| Schreier, L | 1 |
| McCoy, M | 1 |
| Lucero, D | 1 |
| Fassio, E | 1 |
| Billheimer, J | 1 |
| Rader, DJ | 2 |
| Berg, G | 1 |
| Caminhotto, Rde O | 1 |
| Campaña, AB | 1 |
| Lima, FB | 1 |
| Kitamoto, A | 1 |
| Kitamoto, T | 1 |
| Nakamura, T | 1 |
| Ogawa, Y | 1 |
| Yoneda, M | 1 |
| Hyogo, H | 1 |
| Ochi, H | 1 |
| Mizusawa, S | 1 |
| Ueno, T | 1 |
| Nakao, K | 1 |
| Sekine, A | 1 |
| Chayama, K | 1 |
| Nakajima, A | 1 |
| Hotta, K | 1 |
| Ueno, H | 1 |
| Nakazato, M | 1 |
| Rametta, R | 1 |
| Macchi, C | 1 |
| Fracanzani, AL | 1 |
| Steffani, L | 1 |
| Del Ben, M | 1 |
| Polimeni, L | 1 |
| Brancorsini, M | 1 |
| Di Costanzo, A | 1 |
| D'Erasmo, L | 1 |
| Baratta, F | 1 |
| Loffredo, L | 1 |
| Pastori, D | 1 |
| Pignatelli, P | 1 |
| Violi, F | 1 |
| Arca, M | 1 |
| Angelico, F | 1 |
| Shirakawa, T | 1 |
| Nakajima, K | 1 |
| Yatsuzuka, S | 1 |
| Shimomura, Y | 1 |
| Kobayashi, J | 1 |
| Machida, T | 1 |
| Sumino, H | 1 |
| Murakami, M | 1 |
| Villiger, A | 1 |
| Sala, F | 1 |
| Suter, A | 1 |
| Butterweck, V | 1 |
| Mangge, H | 2 |
| Baumgartner, BG | 1 |
| Zelzer, S | 1 |
| Prüller, F | 1 |
| Schnedl, WJ | 1 |
| Reininghaus, EZ | 1 |
| Haybaeck, J | 1 |
| Lackner, C | 1 |
| Stauber, R | 1 |
| Aigner, E | 2 |
| Weghuber, D | 1 |
| Traussnigg, S | 2 |
| Kienbacher, C | 2 |
| Halilbasic, E | 1 |
| Rechling, C | 1 |
| Kazemi-Shirazi, L | 1 |
| Hofer, H | 1 |
| Munda, P | 1 |
| Trauner, M | 2 |
| Baumgartner, B | 1 |
| Schnedl, W | 1 |
| Liu, Z | 1 |
| Que, S | 1 |
| Zhou, L | 1 |
| Zheng, S | 1 |
| Wainwright, P | 1 |
| Kalia, HS | 1 |
| Gaglio, PJ | 1 |
| Andrés-Blasco, I | 1 |
| Vinué, Á | 1 |
| Herrero-Cervera, A | 1 |
| Martínez-Hervás, S | 1 |
| Nuñez, L | 1 |
| Piqueras, L | 1 |
| Ascaso, JF | 1 |
| Sanz, MJ | 1 |
| Burks, DJ | 1 |
| González-Navarro, H | 1 |
| Christiansen, MK | 1 |
| Jensen, JM | 1 |
| Brøndberg, AK | 1 |
| Bøtker, HE | 1 |
| Jensen, HK | 1 |
| Orqueda, ME | 1 |
| Rivas, M | 1 |
| Zampini, IC | 1 |
| Alberto, MR | 1 |
| Torres, S | 1 |
| Cuello, S | 1 |
| Sayago, J | 1 |
| Thomas-Valdes, S | 1 |
| Isla, MI | 1 |
| Stättermayer, AF | 1 |
| Huber-Schönauer, U | 1 |
| Steindl-Munda, P | 1 |
| Stadlmayr, A | 1 |
| Wrba, F | 1 |
| Datz, C | 1 |
| Ferenci, P | 1 |
| Kotronen, A | 1 |
| Hakkarainen, A | 1 |
| Sevastianova, K | 1 |
| Bergholm, R | 1 |
| Johansson, LM | 1 |
| Lundbom, N | 1 |
| Rissanen, A | 1 |
| Ridderstråle, M | 1 |
| Groop, L | 1 |
| Kohlwein, SD | 1 |
| Zhou, YJ | 1 |
| Li, YY | 1 |
| Nie, YQ | 1 |
| Yang, H | 1 |
| Zhan, Q | 1 |
| Huang, J | 1 |
| Shi, SL | 1 |
| Lai, XB | 1 |
| Huang, HL | 1 |
| Speliotes, EK | 1 |
| Butler, JL | 1 |
| Palmer, CD | 1 |
| Voight, BF | 1 |
| Hirschhorn, JN | 1 |
| Ko, JS | 1 |
| Küpeli, E | 1 |
| Ulubay, G | 1 |
| Ulasli, SS | 1 |
| Sahin, T | 1 |
| Erayman, Z | 1 |
| Gürsoy, A | 1 |
| Grove, KA | 1 |
| Sae-tan, S | 1 |
| Kennett, MJ | 1 |
| Lambert, JD | 1 |
| Ackerman, D | 1 |
| Gems, D | 1 |
| Ampuero, J | 1 |
| Romero-Gómez, M | 1 |
| van Hees, AM | 1 |
| Jocken, JW | 1 |
| Essers, Y | 1 |
| Roche, HM | 1 |
| Saris, WH | 1 |
| Blaak, EE | 1 |
| Krarup, NT | 1 |
| Grarup, N | 1 |
| Banasik, K | 1 |
| Friedrichsen, M | 1 |
| Færch, K | 1 |
| Sandholt, CH | 1 |
| Jørgensen, T | 1 |
| Poulsen, P | 1 |
| Witte, DR | 1 |
| Vaag, A | 1 |
| Sørensen, T | 1 |
| Pedersen, O | 1 |
| Hansen, T | 1 |
| Li, Q | 1 |
| Qu, HQ | 1 |
| Rentfro, AR | 1 |
| Grove, ML | 1 |
| Mirza, S | 1 |
| Lu, Y | 1 |
| Hanis, CL | 1 |
| Fallon, MB | 1 |
| Boerwinkle, E | 1 |
| Fisher-Hoch, SP | 1 |
| McCormick, JB | 1 |
| Sakulnarmrat, K | 1 |
| Brunzell, JD | 1 |
| Ayyobi, AF | 1 |
| Didangelos, TP | 1 |
| Thanopoulou, AK | 1 |
| Bousboulas, SH | 1 |
| Sambanis, CL | 1 |
| Athyros, VG | 1 |
| Spanou, EA | 1 |
| Dimitriou, KC | 1 |
| Pappas, SI | 1 |
| Karamanos, BG | 1 |
| Karamitsos, DT | 1 |
| Hansel, B | 1 |
| Kontush, A | 1 |
| Twickler, MT | 1 |
| Stancáková, A | 1 |
| Baldaufová, L | 1 |
| Javorský, M | 1 |
| Kozárová, M | 1 |
| Salagovic, J | 1 |
| Tkác, I | 1 |
| Badellino, KO | 1 |
| Wolfe, ML | 1 |
| Reilly, MP | 1 |
| Kusunoki, J | 1 |
| Kanatani, A | 1 |
| Moller, DE | 1 |
| Langin, D | 1 |
| Lamarche, B | 1 |
| Paradis, ME | 1 |
| Köhler, J | 1 |
| Wünsch, B | 1 |
| Westphal, S | 1 |
| Luley, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Non Invasive Evaluation of Liver Fibrosis and Steatosis in Type 2 Diabetic Patient in Assiut University Hospitals[NCT05605717] | 60 participants (Anticipated) | Observational | 2022-11-01 | Not yet recruiting | |||
| Clinical Study on the Value of Quantitative MRI Imaging in Diffuse Liver Diseases[NCT04626492] | 150 participants (Anticipated) | Observational [Patient Registry] | 2020-08-01 | Recruiting | |||
| Effect of Intermittent Calorie Restriction on Metabolic Dysfunction-Associated Steatotic Liver Disease Patients With Abnormal Glucose Metabolism[NCT04283942] | 60 participants (Actual) | Interventional | 2020-07-30 | Completed | |||
| Study for the Investigation of New Individual Risk Profiles and Therapeutic Strategies in Obesity Related Cardiovascular and Metabolic Disorders.[NCT00482924] | 1,500 participants (Anticipated) | Observational | 2003-01-31 | Recruiting | |||
| Optimizing the Beneficial Health Effects of Exercise for Diabetes: Focus on the Liver![NCT01317576] | 81 participants (Actual) | Interventional | 2011-03-31 | Completed | |||
| Study of Metabolism Influence in Human Alcoholic Liver Disease[NCT01122797] | 658 participants (Actual) | Observational | 2003-01-31 | Completed | |||
| LIPGENE Dietary Intervention Study[NCT00429195] | 480 participants | Interventional | 2004-02-29 | Completed | |||
| A Randomised Controlled International Multicentre Study Evaluating Changes in Metabolic Syndrome in Smokers With Type 2 Diabetes Mellitus After Switching From Tobacco Cigarettes to Combustion-Free Nicotine Delivery Systems: DIASMOKE Study[NCT04231838] | 576 participants (Anticipated) | Interventional | 2021-09-27 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
29 reviews available for 1-anilino-8-naphthalenesulfonate and Metabolic Syndrome
| Article | Year |
|---|---|
Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology.
Topics: 17-Hydroxysteroid Dehydrogenases; Acyltransferases; Adaptor Proteins, Signal Transducing; Carcinoma, | 2020 |
Low serum amylase, lipase, and trypsin as biomarkers of metabolic disorders: A systematic review and meta-analysis.
Topics: Amylases; Biomarkers; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Humans; Lipase; Metaboli | 2020 |
Effect of the patatin-like phospholipase domain containing 3 gene (PNPLA3) I148M polymorphism on the risk and severity of nonalcoholic fatty liver disease and metabolic syndromes: A meta-analysis of paediatric and adolescent individuals.
Topics: Adolescent; Child; Female; Genetic Predisposition to Disease; Humans; Lipase; Male; Membrane Protein | 2020 |
Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma.
Topics: 17-Hydroxysteroid Dehydrogenases; Animals; Apoptosis; Carcinoma, Hepatocellular; Diet, High-Fat; Dis | 2020 |
Epidemiology of nonalcoholic fatty liver disease in non-obese populations: Meta-analytic assessment of its prevalence, genetic, metabolic, and histological profiles.
Topics: Diabetes Mellitus; Humans; Lipase; Membrane Proteins; Metabolic Syndrome; Non-alcoholic Fatty Liver | 2020 |
Nonalcoholic fatty liver disease or metabolic dysfunction-associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches.
Topics: Acyltransferases; Cardiovascular Diseases; Coronary Artery Disease; Diabetes Mellitus, Type 2; Dysli | 2021 |
New trends on obesity and NAFLD in Asia.
Topics: Asia; Body Mass Index; Diet; Genetic Predisposition to Disease; Hepatitis B, Chronic; Humans; Incide | 2017 |
New trends on obesity and NAFLD in Asia.
Topics: Asia; Body Mass Index; Diet; Genetic Predisposition to Disease; Hepatitis B, Chronic; Humans; Incide | 2017 |
New trends on obesity and NAFLD in Asia.
Topics: Asia; Body Mass Index; Diet; Genetic Predisposition to Disease; Hepatitis B, Chronic; Humans; Incide | 2017 |
New trends on obesity and NAFLD in Asia.
Topics: Asia; Body Mass Index; Diet; Genetic Predisposition to Disease; Hepatitis B, Chronic; Humans; Incide | 2017 |
New trends on obesity and NAFLD in Asia.
Topics: Asia; Body Mass Index; Diet; Genetic Predisposition to Disease; Hepatitis B, Chronic; Humans; Incide | 2017 |
New trends on obesity and NAFLD in Asia.
Topics: Asia; Body Mass Index; Diet; Genetic Predisposition to Disease; Hepatitis B, Chronic; Humans; Incide | 2017 |
New trends on obesity and NAFLD in Asia.
Topics: Asia; Body Mass Index; Diet; Genetic Predisposition to Disease; Hepatitis B, Chronic; Humans; Incide | 2017 |
New trends on obesity and NAFLD in Asia.
Topics: Asia; Body Mass Index; Diet; Genetic Predisposition to Disease; Hepatitis B, Chronic; Humans; Incide | 2017 |
New trends on obesity and NAFLD in Asia.
Topics: Asia; Body Mass Index; Diet; Genetic Predisposition to Disease; Hepatitis B, Chronic; Humans; Incide | 2017 |
NAFLD-NASH: An Under-Recognized Epidemic.
Topics: Coronary Artery Disease; Epidemics; Female; Genetic Predisposition to Disease; Global Health; Hispan | 2018 |
Nonalcoholic Fatty Liver Disease and Metabolic Syndrome.
Topics: Dyslipidemias; Humans; Hyperglycemia; Hypertension; Lipase; Membrane Proteins; Metabolic Syndrome; N | 2018 |
Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis in Liver Transplantation.
Topics: Cardiovascular Diseases; Diabetes Complications; Humans; Kidney Diseases; Lipase; Liver Transplantat | 2018 |
Risk Factors for the Development of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Genetics.
Topics: Acyltransferases; Asian People; Black or African American; Diabetes Mellitus, Type 2; Female; Hispan | 2018 |
Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome.
Topics: Diabetes Mellitus, Type 2; Fatty Liver; Female; Humans; Lipase; Male; Membrane Proteins; Metabolic S | 2014 |
[Cutting-edge of medicine; the prospects of novel anti-obesity drugs].
Topics: Anti-Obesity Agents; Appetite; Appetite Depressants; Benzazepines; Benzoxazines; Bupropion; Clinical | 2014 |
A Perspective on Metabolic Syndrome and Nonalcoholic Fatty Liver Disease.
Topics: Biomarkers; Diabetes Mellitus, Type 2; Genetic Predisposition to Disease; Genetic Variation; Humans; | 2015 |
Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
Topics: Anticholesteremic Agents; Antioxidants; Bariatric Surgery; Carcinoma, Hepatocellular; Disease Progre | 2015 |
Bidirectional Relationships and Disconnects between NAFLD and Features of the Metabolic Syndrome.
Topics: Animals; Female; Genetic Predisposition to Disease; Genetic Variation; Genotype; Humans; Insulin Res | 2016 |
The Prevalence and Pathobiology of Nonalcoholic Fatty Liver Disease in Patients of Different Races or Ethnicities.
Topics: Black or African American; Hispanic or Latino; Humans; Lipase; Membrane Proteins; Metabolic Syndrome | 2016 |
Diagnosis of non-alcoholic fatty liver disease (NAFLD).
Topics: Alanine Transaminase; Genotype; Humans; Lipase; Membrane Proteins; Metabolic Syndrome; Non-alcoholic | 2016 |
Obese and anorexic yeasts: experimental models to understand the metabolic syndrome and lipotoxicity.
Topics: Animals; Anorexia; Fatty Acids; Humans; Lipase; Lipid Peroxidation; Metabolic Syndrome; Models, Biol | 2010 |
Liver fat in the pathogenesis of insulin resistance and type 2 diabetes.
Topics: Adipose Tissue; Diabetes Mellitus, Type 2; Fatty Liver; Glucose; Humans; Insulin; Insulin Resistance | 2010 |
[Nonalcoholic fatty liver disease].
Topics: Diet; Fatty Liver; Humans; Inflammation Mediators; Insulin Resistance; Lipase; Membrane Proteins; Me | 2010 |
The mystery of C. elegans aging: an emerging role for fat. Distant parallels between C. elegans aging and metabolic syndrome?
Topics: Aging; Animals; Caenorhabditis elegans; Homeostasis; Lipase; Lipids; Longevity; Metabolic Syndrome; | 2012 |
[Influence of non-alcoholic fatty liver disease on cardiovascular disease].
Topics: Apolipoprotein C-III; Atherosclerosis; Cardiovascular Diseases; Carotid Intima-Media Thickness; Chol | 2012 |
The PNPLA3 rs738409 G-allele associates with reduced fasting serum triglyceride and serum cholesterol in Danes with impaired glucose regulation.
Topics: Body Mass Index; Case-Control Studies; Cholesterol; Denmark; Dyslipidemias; Fasting; Female; Gene Fr | 2012 |
Dyslipidemia in the metabolic syndrome and type 2 diabetes mellitus.
Topics: Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus, Type 2; Humans; Hype | 2003 |
High-density lipoprotein as a key component in the prevention of premature atherosclerotic disease in the insulin resistance syndrome.
Topics: Apolipoproteins B; Arteriosclerosis; Diabetes Mellitus, Type 2; Esterification; Homeostasis; Humans; | 2004 |
Modulation of fatty acid metabolism as a potential approach to the treatment of obesity and the metabolic syndrome.
Topics: Acetyl-CoA Carboxylase; AMP-Activated Protein Kinases; Animals; Anti-Obesity Agents; Diacylglycerol | 2006 |
Adipose tissue lipolysis as a metabolic pathway to define pharmacological strategies against obesity and the metabolic syndrome.
Topics: Adipose Tissue; GTP-Binding Protein alpha Subunits, Gi-Go; Humans; Lipase; Lipolysis; Metabolic Synd | 2006 |
Endothelial lipase and the metabolic syndrome.
Topics: Animals; Cholesterol Ester Transfer Proteins; Humans; Hypertension; Inflammation; Lipase; Lipoprotei | 2007 |
4 trials available for 1-anilino-8-naphthalenesulfonate and Metabolic Syndrome
| Article | Year |
|---|---|
Adipose triglyceride lipase and hormone-sensitive lipase protein expression in subcutaneous adipose tissue is decreased after an isoenergetic low-fat high-complex carbohydrate diet in the metabolic syndrome.
Topics: Adiposity; Aged; Dietary Carbohydrates; Dietary Fats; Female; Humans; Insulin Resistance; Lipase; Ma | 2012 |
PNPLA3 polymorphisms and liver aminotransferase levels in a Mexican American population.
Topics: Adult; Age Factors; Alanine Transaminase; Aspartate Aminotransferases; Female; Genotype; Humans; Lip | 2012 |
The ORLIstat and CArdiovascular risk profile in patients with metabolic syndrome and type 2 DIAbetes (ORLICARDIA) Study.
Topics: Anti-Obesity Agents; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diet, Reduci | 2004 |
Preferential increase in high-molecular weight adiponectin after niacin.
Topics: Adiponectin; Cholesterol, HDL; Cholesterol, LDL; Delayed-Action Preparations; Fatty Acids, Nonesteri | 2008 |
47 other studies available for 1-anilino-8-naphthalenesulfonate and Metabolic Syndrome
| Article | Year |
|---|---|
Association of rs738409 Polymorphism in Adiponutrin Gene with Liver Steatosis and Atherosclerosis Risk Factors in Greek Children and Adolescents.
Topics: Acyltransferases; Adolescent; Atherosclerosis; Child; Genetic Predisposition to Disease; Genotype; G | 2022 |
Deficiency of Adipose Triglyceride Lipase Induces Metabolic Syndrome and Cardiomyopathy in Zebrafish.
Topics: Adipose Tissue; Animals; Cardiomyopathies; CRISPR-Associated Protein 9; Lipase; Lipolysis; Metabolic | 2022 |
Associations between Endothelial Lipase, High-Density Lipoprotein, and Endothelial Function Differ in Healthy Volunteers and Metabolic Syndrome Patients.
Topics: Apolipoprotein A-I; Cholesterol; Cholesterol, HDL; Healthy Volunteers; Humans; Lipase; Lipoproteins, | 2023 |
Modulatory Effect of Pyrus pyrifolia Fruit and its Phenolics on Key Enzymes against Metabolic Syndrome: Bioassay-Guided Approach, HPLC Analysis, and In Silico Study.
Topics: alpha-Amylases; alpha-Glucosidases; Antioxidants; Chromatography, High Pressure Liquid; Fruit; Lipas | 2023 |
Associations between Endothelial Lipase and Apolipoprotein B-Containing Lipoproteins Differ in Healthy Volunteers and Metabolic Syndrome Patients.
Topics: Apolipoproteins B; Cholesterol; Healthy Volunteers; Humans; Lipase; Lipoproteins; Lipoproteins, LDL; | 2023 |
Antioxidant capacity and inhibition of metabolic syndrome-associated enzymes by Cryptocarya alba fruits.
Topics: alpha-Glucosidases; Antioxidants; Catechin; Cryptocarya; Fruit; Lipase; Metabolic Syndrome; Phenols; | 2023 |
PNPLA3 I148M Polymorphism in Patients with Nonalcoholic Fatty Liver Disease, Obesity and Prediabetes.
Topics: Adult; Aged; Anthropometry; Female; Genetic Predisposition to Disease; Genotype; Humans; Lipase; Mal | 2019 |
Association of metabolic syndrome and patatin-like phospholipase 3 - rs738409 gene variant in non-alcoholic fatty liver disease among a Chennai-based south Indian population.
Topics: Adult; Aged; Alleles; Biomarkers; Case-Control Studies; Disease Susceptibility; Female; Genetic Pred | 2020 |
The effect of PNPLA3 polymorphism as gain in function mutation in the pathogenesis of non-alcoholic fatty liver disease.
Topics: Carcinoma, Hepatocellular; Deception; Humans; Lipase; Liver Neoplasms; Membrane Proteins; Metabolic | 2020 |
Hydromethanolic Extracts from
Topics: Adansonia; Adipocytes; alpha-Amylases; Angiotensin-Converting Enzyme Inhibitors; Cell Differentiatio | 2020 |
PNPLA3 gene polymorphism is associated with liver steatosis in children with Down syndrome.
Topics: Adiponectin; Adolescent; Age Factors; Biomarkers; Blood Glucose; Child; Child, Preschool; Down Syndr | 2020 |
Individualized Polygenic Risk Score Identifies NASH in the Eastern Asia Region: A Derivation and Validation Study.
Topics: 17-Hydroxysteroid Dehydrogenases; Adult; Biopsy; China; Cross-Sectional Studies; Female; Genetic Pre | 2021 |
Metabolic Syndrome Modulates Association between Endothelial Lipase and Lipid/Lipoprotein Plasma Levels in Acute Heart Failure Patients.
Topics: Aged; Aged, 80 and over; Female; Heart Failure; Humans; Lipase; Lipids; Lipoproteins; Male; Metaboli | 2017 |
Identification of potential inhibitory peptides of enzymes involved in the metabolic syndrome obtained by simulated gastrointestinal digestion of fermented bean (Phaseolus vulgaris L.) seeds.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Digestion; Fermentation; Humans; Lipase; Metaboli | 2017 |
PNPLA3 rs738409 Polymorphism Predicts Development and Severity of Hepatic Steatosis but Not Metabolic Syndrome in Celiac Disease.
Topics: Adolescent; Adult; Alleles; Celiac Disease; Diet, Gluten-Free; Fatty Liver; Female; Genetic Predispo | 2018 |
Amelioration of experimental metabolic syndrome induced in rats by orlistat and Corchorus olitorius leaf extract; role of adipo/cytokines.
Topics: Adiponectin; Animals; Anti-Obesity Agents; Corchorus; Cytokines; Diet, High-Fat; Hyperlipidemias; In | 2019 |
Comparative study of overweight and obese patients with nonalcoholic fatty liver disease.
Topics: Adiponectin; Adult; Analysis of Variance; Biopsy, Needle; Body Mass Index; Cross-Sectional Studies; | 2019 |
Active Components, Antioxidant, Inhibition on Metabolic Syndrome Related Enzymes, and Monthly Variations in Mature Leaf Hawk Tea.
Topics: alpha-Glucosidases; Antioxidants; China; Drugs, Chinese Herbal; Flavonoids; Glycoside Hydrolase Inhi | 2019 |
Adipose HuR protects against diet-induced obesity and insulin resistance.
Topics: Adipocytes; Adipose Tissue; Adipose Tissue, White; Animals; Cell Enlargement; Diet, High-Fat; ELAV-L | 2019 |
Altered lipid homeostasis in Drosophila InsP3 receptor mutants leads to obesity and hyperphagia.
Topics: Adiposity; Animals; Appetite; Body Weight; Drosophila melanogaster; Drosophila Proteins; Fatty Acids | 2013 |
Phenolic composition, antioxidant and enzyme inhibitory activities of Eryngium bornmuelleri leaf.
Topics: alpha-Amylases; Antioxidants; Enzyme Inhibitors; Eryngium; Glycoside Hydrolase Inhibitors; Humans; L | 2014 |
A population-based study on the prevalence of NASH using scores validated against liver histology.
Topics: Adolescent; Adult; Aged; Biopsy; Cohort Studies; Diabetes Mellitus, Type 2; Female; Finland; Humans; | 2014 |
PNPLA3 gene polymorphism accounts for fatty liver in community subjects without metabolic syndrome.
Topics: Adult; Diet; Fatty Liver; Female; Humans; Lipase; Male; Membrane Proteins; Metabolic Syndrome; Middl | 2014 |
Role of SN1 lipases on plasma lipids in metabolic syndrome and obesity.
Topics: Adult; Apolipoprotein A-I; Body Mass Index; Cholesterol, HDL; Cholesterol, LDL; Fatty Acids, Noneste | 2014 |
[Lipolysis inhibition as therapeutic target in the metabolic syndrome].
Topics: Adipocytes; Adipose Tissue; Enzyme Activation; Humans; Insulin Resistance; Lipase; Lipolysis; Metabo | 2014 |
Association of polymorphisms in GCKR and TRIB1 with nonalcoholic fatty liver disease and metabolic syndrome traits.
Topics: Adaptor Proteins, Signal Transducing; Adult; Alleles; Case-Control Studies; Female; Gene Frequency; | 2014 |
Hepatic steatosis and PNPLA3 I148M variant are associated with serum Fetuin-A independently of insulin resistance.
Topics: Adiponectin; alpha-2-HS-Glycoprotein; Cross-Sectional Studies; Fatty Acids, Nonesterified; Fatty Liv | 2014 |
Non-alcoholic fatty liver disease, metabolic syndrome and patatin-like phospholipase domain-containing protein3 gene variants.
Topics: Adult; Aged; Cardiovascular Diseases; Cohort Studies; Female; Genetic Predisposition to Disease; Hum | 2014 |
The role of circulating lipoprotein lipase and adiponectin on the particle size of remnant lipoproteins in patients with diabetes mellitus and metabolic syndrome.
Topics: Adiponectin; Adult; Case-Control Studies; Cholesterol; Cholesterol, LDL; Diabetes Mellitus, Type 2; | 2015 |
In vitro inhibitory potential of Cynara scolymus, Silybum marianum, Taraxacum officinale, and Peumus boldus on key enzymes relevant to metabolic syndrome.
Topics: Angiotensin-Converting Enzyme Inhibitors; Cynara scolymus; Enzyme Inhibitors; Flavonoids; Glycoside | 2015 |
Patatin-like phospholipase 3 (rs738409) gene polymorphism is associated with increased liver enzymes in obese adolescents and metabolic syndrome in all ages.
Topics: Adolescent; Adult; Aged; Alleles; Case-Control Studies; Child; Female; Genotype; Heterozygote; Human | 2015 |
Letter: PNPLA3, metabolic syndrome and NAFLD status in obese subjects--authors' reply.
Topics: Female; Humans; Lipase; Male; Membrane Proteins; Metabolic Syndrome; Non-alcoholic Fatty Liver Disea | 2015 |
Letter: PNPLA3, metabolic syndrome and NAFLD status in obese subjects.
Topics: Female; Humans; Lipase; Male; Membrane Proteins; Metabolic Syndrome; Non-alcoholic Fatty Liver Disea | 2015 |
Hepatic lipase inactivation decreases atherosclerosis in insulin resistance by reducing LIGHT/Lymphotoxin β-Receptor pathway.
Topics: Animals; Atherosclerosis; Diet, Atherogenic; Disease Models, Animal; Humans; Inflammation Mediators; | 2016 |
Cardiovascular risk factor control is insufficient in young patients with coronary artery disease.
Topics: Adult; Age of Onset; Antihypertensive Agents; Biomarkers; Blood Pressure; Body Mass Index; Cholester | 2016 |
Chemical and functional characterization of seed, pulp and skin powder from chilto (Solanum betaceum), an Argentine native fruit. Phenolic fractions affect key enzymes involved in metabolic syndrome and oxidative stress.
Topics: alpha-Amylases; alpha-Glucosidases; Antioxidants; Argentina; Ascorbic Acid; Carotenoids; Cinnamates; | 2017 |
Low hepatic copper content and PNPLA3 polymorphism in non-alcoholic fatty liver disease in patients without metabolic syndrome.
Topics: Adult; Copper; Female; Humans; Lipase; Liver; Male; Membrane Proteins; Metabolic Syndrome; Middle Ag | 2017 |
Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors.
Topics: Adult; Diabetes Mellitus, Type 2; Fatty Liver; Female; Genotype; Humans; Lipase; Lipids; Liver; Magn | 2009 |
Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors.
Topics: Adult; Diabetes Mellitus, Type 2; Fatty Liver; Female; Genotype; Humans; Lipase; Lipids; Liver; Magn | 2009 |
Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors.
Topics: Adult; Diabetes Mellitus, Type 2; Fatty Liver; Female; Genotype; Humans; Lipase; Lipids; Liver; Magn | 2009 |
Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors.
Topics: Adult; Diabetes Mellitus, Type 2; Fatty Liver; Female; Genotype; Humans; Lipase; Lipids; Liver; Magn | 2009 |
Influence of polygenetic polymorphisms on the susceptibility to non-alcoholic fatty liver disease of Chinese people.
Topics: Adiponectin; Adult; Aged; Asian People; Case-Control Studies; Chi-Square Distribution; China; Fatty | 2010 |
PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease.
Topics: Adult; Alleles; Biopsy; Case-Control Studies; Disease Progression; Fatty Liver; Female; Genetic Pred | 2010 |
Metabolic syndrome is associated with increased risk of acute exacerbation of COPD: a preliminary study.
Topics: Acute Disease; Aged; C-Reactive Protein; Case-Control Studies; Female; Humans; Inflammation; Lipase; | 2010 |
(-)-Epigallocatechin-3-gallate inhibits pancreatic lipase and reduces body weight gain in high fat-fed obese mice.
Topics: Animals; Antioxidants; Body Weight; Catechin; Diet, High-Fat; Feces; Lipase; Lipids; Male; Metabolic | 2012 |
Composition of native Australian herbs polyphenolic-rich fractions and in vitro inhibitory activities against key enzymes relevant to metabolic syndrome.
Topics: alpha-Glucosidases; Animals; Australia; Enzyme Inhibitors; Glycoside Hydrolase Inhibitors; Humans; K | 2012 |
Effect of gene polymorphisms on lipoprotein levels in patients with dyslipidemia of metabolic syndrome.
Topics: Aged; Apolipoprotein C-III; Apolipoproteins B; Cholesterol; Cholesterol Ester Transfer Proteins; Cho | 2006 |
Endothelial lipase concentrations are increased in metabolic syndrome and associated with coronary atherosclerosis.
Topics: Adult; Aged; Anticoagulants; Cholesterol, HDL; Coronary Artery Disease; Cross-Sectional Studies; Enz | 2006 |
Rimonabant: new drug. Obesity: loss of a few kilos, many questions.
Topics: Anti-Obesity Agents; Cholesterol, HDL; Diet, Reducing; Double-Blind Method; Drug Approval; Europe; E | 2006 |
The allosteric modulation of lipases and its possible biological relevance.
Topics: Adipose Tissue; Allosteric Regulation; Animals; Burkholderia cepacia; Computer Simulation; Energy Me | 2007 |